{
    "nct_id": "NCT05415722",
    "official_title": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy as Well as in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic Steatohepatitis (NASH)",
    "inclusion_criteria": "* Male or female, 18 to 75 years of age\n* Overweight or obese with a body mass index (BMI) â‰¥ 25 kg/m2\n* Presumed NASH diagnosed by prior biopsy and/or imaging criteria\n* Written informed consent\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 75 Years",
    "exclusion_criteria": "* History or clinical evidence of chronic liver diseases other than NAFLD\n* History or known clinical evidence of cirrhosis, esophageal varices, hepatic decompensation or other severe liver impairment,\n* History of liver transplant, or current placement on a liver transplant list\n* Current diagnosis or history of pituitary or thyroid disorders - except for patients with primary hypothyroidism on a stable dose of thyroid hormone replacement therapy.\n* Abnormal TSH or free T4 levels\n* Weight loss of > 5% total body weight within 3 months prior to Screening\n* Uncontrolled diabetes\n* Uncontrolled hyperlipidemia\n* Unstable cardiovascular disease\n* Excessive alcohol consumption\n\nOther protocol-defined I/E criteria that apply.",
    "miscellaneous_criteria": "Key"
}